Clinical Trial Update: Study of Epratuzumab in Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 study of the monoclonal antibody epratuzumab for systemic lupus erythematosus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Epratuzumab (epratuzumab)

Snippet

Sponsor: UCB Pharma | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: TERMINATED